Status: Finalised First registered on: 30/03/2016
Last updated on: 19/12/2018
1. Study identification
EU PAS Register NumberEUPAS12987
Official titleEvaluation of the undertreatment and disease outcomes for patients with coexisting Heart Failure and Chronic Obstructive Pulmonary Disease
Study title acronym
Study typeObservational study
Brief description of the studyThe objectives of this study are to assess the prevalence of comorbid diagnosed COPD and HF and to describe therapies prescribed and diagnostic tests undertaken by clinicians in real-life clinical practice for patients with COPD and/or HF. Additionally, it will evaluate the long-term respiratory and cardiovascular outcomes associated with the prescribed therapies for patients with comorbid COPD and HF. This study will be conducted using historical data from patients with COPD and/or heart failure. The prevalence of comorbid diagnosed COPD and HF will be assessed at the time of most recent data available for each patient, from all patients with a diagnosis of either COPD and/or HF. COPD and HF therapies prescribed and diagnostic tests undertaken will be considered in the year prior to most recent data available, between January 2010 to date for patients, comparing patients with comorbid COPD and HF to those with COPD alone and to those with HF alone. Cardiovascular and respiratory outcomes will be assessed for patients with comorbid COPD and HF, comparing those with adequate versus inadequate treatment for COPD/HF (according to guidelines). These outcomes will be assessed over at least one year and up to three years.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsOPRI Pte Ltd
Department/Research groupResearch in Real Life Ltd
Organisation/affiliationOPRI Pte Ltd
Website/Homepagewww.opri.org
Details of (Primary) lead investigator
Title Miss
Last name Martin
First name Jessica
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
National study

United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed20/11/2015
Start date of data collection05/02/2016
Start date of data analysis
Date of interim report, if expected
Date of final study report13/03/201708/12/2017
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesNovartis100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 160 Paya Lebar Road
Address line 2Paya Lebar Square 
Address line 3Level 5, Unit 33 & 34 
CitySingapore 
Postcode409051 
CountrySingapore
Phone number (incl. country code)6568097251 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg
Public Enquiries
Title Professor 
Last name Price 
First name David 
Address line 160 Paya Lebar Road 
Address line 2Paya Lebar Square 
Address line 3Level 5, Unit 33 & 34 
CitySingapore 
Postcode409051 
CountrySingapore 
Phone number (incl. country code)6568097251 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg 
Top